Randomized, Double-Blind, Double-Dummy, Placebo- and Positive Controlled, 4-Way Crossover Study to Assess the Effect of Single-Dose ACP-196 on the QTc Interval in Healthy Adult Subjects
Latest Information Update: 06 May 2021
At a glance
- Drugs Acalabrutinib (Primary) ; Moxifloxacin
- Indications B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Glioma; Haematological malignancies; Head and neck cancer; Infections; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Pharmacodynamics
- Sponsors Acerta Pharma
- 06 May 2021 New trial record